This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Nasacort Allergy 24 HR, triamcinolone actonide
Description: Nasacort AQ is an aqueous-based (AQ) corticosteroid nasal spray that contains triamcinolone acetonide.
Deal Structure: Nasacort AQ was originally developed by Rhone-Poulenc Rorer Pharmaceuticals.
In January 1999, Rhone-Poulenc merged with Hoechst to form Aventis.
In 2004, Aventis merged with Sanofi-Synthelabo to form Sanofi-Aventis.
Nasacort AQ News
Pink Sheet In Brief: Rhone-Poulenc Rorer's Nasacort AQ
Pink Sheet In Brief: Rorer's Nasacort AQ Nasal Spray
Additional information available to subscribers only: